# W4 — UFO/OntoUML Conceptualization Closure Report

## Status
**W4 implementation: COMPLETE**

**Gate D: APPROVED on 2026-08-19**

## Issues covered
- V2-036 / #58 — Core and Extension architecture
- V2-037 / #59 — UFO analysis of object/agent/product/role types
- V2-038 / #60 — Relators and material relations
- V2-039 / #61 — Events, situations, observations and temporal participation
- V2-040 / #62 — Geography, facilities and regulatory jurisdiction
- V2-041 / #63 — Pharmaceutical Ecosystem Risk & Resilience Extension
- V2-042 / #64 — Business Architecture as optional analytical view
- V2-043 / #65 — Integrated OntoUML conceptual model and decision registry
- V2-044 / #66 — OntoUML anti-pattern/semantic review and Gate D

## Approved W4 conceptual inventory
- 32 Core types/pattern elements
- 25 cross-cutting infrastructure elements
- 30 modular extension elements
- **87 total named conceptual types/pattern elements**
- 2 W3 candidates remain deferred

## Principal conceptual decisions
- Organization, Facility, Geography and Jurisdiction are separate identity layers.
- Ecosystem Participant is a RoleMixin; specific manufacturer/importer/distributor/authority/site concepts are Roles, not Kinds.
- Registration and Authorization are Relators, while source documents/IDs remain evidence.
- Product, Substance and Presentation are distinct Kinds; Strength is a Quality.
- Essential/Critical classifications are contextual Relator subkinds, not rigid Product types.
- Medicine Shortage is a Situation; source records/assertions describe it.
- Observation Activity is an Event and Observation Result is an information object.
- Supply Capacity is a Mode/disposition, distinct from observed capacity results.
- Identifier Value is not identity; Identifier Assignment is contextual.
- Evidence/provenance/mapping/entity-match semantics are first-class infrastructure.
- Risk/Resilience and BA remain modular extensions.

## Semantic review
Manual/static review against OntoUML specification and anti-pattern categories: **PASS with bounded residual issues**. This is not represented as an automated OntoUML tool run.

## Held-out integrity
PASS. H1 ClinicalTrials.gov/AACT, H2 openFDA Drug Shortages and H3 selected national EML schemas were not used for W4 Core redesign.

## Decision
**Gate D APPROVED. W5 Formal Ontology Engineering authorized.**

Any material reversal of the frozen Gate D identity/dependence commitments requires a documented design-change review.
